


Supplementary Figure Legends

Supplementary Figure 1S Effects of BBR on the HepG2 cell viability. The cell viability was measured by MTT with BBR treatment at a dose of 0, 5, 10, 20, 30, 40, and 50 $\mu\text{g/ml}$ for 24h (A) and 48h (B). * $P < 0.05$ and ** $P < 0.01$ BBR-treated groups vs Control group.


Supplementary Figure 2S Effects of insulin on the cell viability, glucose consumption and glucose take-up in HepG2 cells. The cell viability was measured by MTT with insulin treatment at a dose of 10^{-5} , 10^{-6} , 10^{-7} and 10^{-8} mol/L for 24h (A) and 48h (B). (C) The glucose consumption was significantly decreased with 10^{-5} or 10^{-6} mol/L insulin treatment. (D) The fall range of glucose consumption was bigger in 36 h after treatment with insulin at a dose of 10^{-6} mol/L. (E) Representative images of glucose take-up in HepG2 cells. (F) The quantitative analysis of fluorescence associated with 2-NBDG take-up. * $P < 0.05$ and ** $P < 0.01$ Insulin groups vs Control group.

Supplementary Figure 3S Efficient PPM1B knockdown at the mRNA and protein levels in human HepG2 cells using lentiviral-mediated RNAi. (A) Representative images of GFP expression in HepG2 cells after infection using shNC or shPPM1B-1/PPM1B-2/PPM1B-3 lentiviruses. PPM1B mRNA (B) and protein(C) expression in HepG2 cells after transfection of shNC or shPPM1B-1 /PPM1B-2 /PPM1B-3 lentiviruses. GAPDH was used as an internal control, and the data represent the mean \pm SD of three independent experiments. (* $P < 0.05$, ** $P < 0.01$; shPPM1B-1/PPM1B-2/PPM1B-3 lentiviruses vs shNC group; Magnification, $\times 100$; Scale bar, $100\mu\text{m}$)

Supplementary Figure 1S



Supplementary Figure 2S



Supplementary Figure 3S




Table S1 Primer of q-PCR

| Primer | Species | Sequence 5'-3' |
|-----------------|--------------|-----------------------------|
| TNF α -F | Homo sapiens | AGGACCAGCTAAGAGGGAGA |
| TNF α -R | Homo sapiens | CCCGGATCATGCTTTCAGTG |
| IL-1 β -F | Homo sapiens | ATGCCACCTTTTGACAGTGATG |
| IL-1 β -R | Homo sapiens | AGCTTCTCCACAGCCACAAT |
| IL-6-F | Homo sapiens | AAGCCAGAGTCATTCAGAGCAATACTG |
| IL-6-R | Homo sapiens | GATGAGTTGGATGGTCTTGGTCCTTAG |
| IL-8-F | Homo sapiens | TTGGCAGCCTTCCTGATTCT |
| IL-8-R | Homo sapiens | TTTGGGGTGGAAAGGTTTGGGA |
| IL-10-F | Homo sapiens | GCCTTCAGCAGAGTGAAGACT |
| IL-10-R | Homo sapiens | GGCAACCCAGGTAACCCTTA |

| | | |
|------------------|--------------|-------------------------|
| PDE3B-F | Homo sapiens | AATGGCCCAGCAAAAAGTTTCG |
| PDE3B-R | Homo sapiens | GAGTTACACAGGGGACCCAC |
| PDE4A-F | Homo sapiens | GCGGGACCTACTGAAGAAATTCC |
| PDE4A-R | Homo sapiens | CAGGGTGGTCCACATCGTGG |
| PPM1B-F | Homo sapiens | GCTTGTGATGGGATCTGGGA |
| PPM1B-R | Homo sapiens | TCTCCATAATCTCTTCAACCCGT |
| IKK β -F | Homo sapiens | AGCTCTGGAACCTCCTGAAGA |
| IKK β -R | Homo sapiens | AGCTCCAGTCTAGGGTCGTGA |
| PPAR γ -F | Homo sapiens | CTGCCGGATCCACAAAAAAG |
| PPAR γ -R | Homo sapiens | CGCCAACAGCTTCTCCTTCTCG |
| LRP1-F | Homo sapiens | TCCTGCCTGCTCCTCAGTAT |
| LRP1-R | Homo sapiens | AGAGCCAAGGAAAGGAAAGC |
| NF κ B-F | Homo sapiens | AGTTGAGGGGACTTCCCAGGC |
| NF κ B -R | Homo sapiens | GCCTGGGAAAGTCCCCTCAACT |
| JNK1-F | Homo sapiens | GTGGGGTATGCCCAAGAGG |
| JNK1-R | Homo sapiens | GCCATAAAGCCCAGATAGAGC |
| GLUT4-F | Homo sapiens | CAGCTCTCAGGCATCAAT |
| GLUT4-R | Homo sapiens | TCTACTAAGAGCACCGAG |
| IRS1-F | Homo sapiens | CAAGAGCATGCACAAACGCT |
| IRS1-R | Homo sapiens | GCCCGCTTGTTGATGTTGAA |
| PI3K p85-F | Homo sapiens | TCCTGCTATGGCAGACATCC |
| PI3K p85-R | Homo sapiens | AGAAATGGTAGCTTCCCGAGG |
| AKT-F | Homo sapiens | TCGGAGACTGACACCAGGTA |
| AKT-R | Homo sapiens | CTGGCCGAGTAGGAGAACTG |
| IRS2-F | Homo sapiens | CTCACCTGTAGTGCCTTCG |
| IRS2-R | Homo sapiens | ATGTTGATGTACTCGCCGGG |
| GAPDH-F | Homo sapiens | CGGGGCTGGCATTGCTCTC |
| GAPDH-R | Homo sapiens | GGGGCCGACTTGGGATAGG |

Table S2 Functional and pathway enrichment analysis of DEGs in BBR (150mg/Kg) group

| Category | Term | Description | Genes | FDR |
|--------------|------------|--|---|------------------|
| GO_BP | GO:0006508 | proteolysis | Capn11,Casp14,Ctsd ,Cma1, Lonp1, Mst1,Sri | 7.4E-3 |
| GO_BP | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | Nfat5, Rcan1 | 1.8E-2 |
| GO_BP | GO:0050771 | negative regulation of axonogenesis | Mbp, Pten | 4.6E-2 |
| GO_MF | GO:0042802 | identical protein binding | Rbmx, Lyc2, Mri1, Pten, Rcan1, Safb2, Sri, Trip10, Tfrc | 3.6E-3 |
| GO_MF | GO:0003727 | single-stranded RNA binding | Rbmx, Hmgb1, Lonp1 | 1.3E-2 |
| GO_MF | GO:0003725 | double-stranded RNA binding | Hsp90ab1, Hmgb1, Tfrc | 3.0E-2 |
| GO_MF | GO:0003723 | poly(A) RNA binding | Rbmx,Fam98a,Hsp90ab1,Hmgb1,Nol8, Ppan, Rps12, Safb2, Tfrc, Zcchc9 | 3.1E-2 |
| GO_MF | GO:0000166 | nucleotide binding | Rbmx, Marf1, Nol8, Rcan1, Safb2 | 3.7E-2 |
| GO_MF | GO:0042277 | peptide binding | Ctsd, Cma1, Hmgb1 Gng5,Lypd2,Rbmx,Arpc1a,Asna1, Casp14, Ctsd, | 3.8E-2 2.1E-2 |
| GO_CC | GO:0070062 | extracellular exosome | Hsp90ab1, Lyc2, Mst1, Pgm2, Safb2, Sri, Tnxb, Trip10, Tfrc, Zfp445 | |
| GO_CC | GO:0005694 | chromosome | Recql, Setd2, Hmgb1 | 3.0E-2 |
| GO_CC | GO:0043231 | Intracellular membrane-bounded organelle | Btaf1, Ahcy12, Cma1, Safb2, Snapc1, Trip10, Tfrc | 3.6E-2 |
| GO_CC | GO:0042470 | melanosome | Ctsd, Hsp90ab1, Tfrc | 4.1E-2 |
| GO_CC | GO:0042995 | cell projection | Mbp, Pten, Trip10 | 4.6E-2 |
| KEGG pathway | hsa04151 | PI3K-Akt signaling pathway | Gng5, Atf6b, Hsp90ab1, Lamb3, Pten | 3.2E-2 |

Abbreviations: GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.BP, biological process; CC, cellular component; MF, molecular functions; FDR, false discovery rate